Ondansentron and Dexamethasone Treatment with Different Dosing Schedules (24 versus 32 mg) in Patients with Non-Small-Cell Lung Cancer under Cisplatin-Based Chemotherapy:A Randomized Stud y

Publisher： Karger

E-ISSN： 1421-9794|46|5|364-370

ISSN： 0009-3157

Source： Chemotherapy, Vol.46, Iss.5, 2000-08, pp. : 364-370

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Randomized Phase II Trial of Gemcitabine plus Carboplatin: Biweekly versus Standard Schedules in Patients with Advanced Non-Small Cell Lung Cancer

By  

Chemotherapy, Vol. 59, Iss. 5, 2014-05 ,pp. : 346-353

Karger

Access to resources Recommend Favorite

Efficacy and Safety of Platinum Combination Chemotherapy Re-Challenge for Relapsed Patients with Non-Small-Cell Lung Cancer after Postoperative Adjuvant Chemotherapy of Cisplatin plus Vinorelbine

By  

Chemotherapy, Vol. 59, Iss. 4, 2014-01 ,pp. : 307-313

Karger

Access to resources Recommend Favorite

Phase II Trial of Biweekly Chemotherapy with Docetaxel and Cisplatin in High-Risk Patients with Unresectable Non-Small Cell Lung Cancer

By  

Chemotherapy, Vol. 59, Iss. 3, 2013-10 ,pp. : 159-166

Karger

Access to resources Recommend Favorite

Bevacizumab-Based Therapy for Patients with Brain Metastases from Non-Small-Cell Lung Cancer: Preliminary Results

By  

Chemotherapy, Vol. 60, Iss. 5-6, 2015-0 ,pp. : 294-299

Karger

Access to resources Recommend Favorite

A Method for Biomarker Directed Survival Prediction in Advanced Non-Small-Cell Lung Cancer Patients Treated with Carboplatin-Based Therapy

By Chen Wei   Bepler Gerold  

Journal of Personalized Medicine, Vol. 3, Iss. 3, 2013-09 ,pp. : 251-262

MDPI

Access to resources Recommend Favorite